Ligand Pharmaceuticals (LGND) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn | 68.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.56% |
| Dec 31, 2025 | 244.06% |
| Mar 31, 2023 | 32.21% |
| Dec 31, 2022 | -32.75% |
| Sep 30, 2022 | -39.70% |
| Jun 30, 2022 | -136.03% |
| Mar 31, 2022 | 47.30% |
| Dec 31, 2021 | -112.64% |
| Sep 30, 2021 | 1.28% |
| Jun 30, 2021 | -125.89% |
| Mar 31, 2021 | 80.69% |
| Dec 31, 2020 | 338.85% |
| Sep 30, 2020 | 56.06% |
| Jun 30, 2020 | 253.17% |
| Mar 31, 2020 | -103.62% |
| Dec 31, 2019 | 82.66% |
| Sep 30, 2019 | -122.64% |
| Jun 30, 2019 | -119.71% |
| Mar 31, 2019 | 1,371.62% |
| Mar 31, 2016 | -73.45% |
| Dec 31, 2015 | 232.04% |
| Sep 30, 2015 | 12,433.98% |
| Jun 30, 2014 | -54.78% |
| Jun 30, 2013 | 33.24% |
| Mar 31, 2013 | -89.79% |
| Mar 31, 2012 | 46,675.00% |
| Sep 30, 2011 | -108.33% |